Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immunomedics, Inc.

http://www.immunomedics.com

Latest From Immunomedics, Inc.

Keeping Track: US FDA Approves Zokinvy, Defers Liso-Cel, Declines ALKS 3831 And Zimhi; Two Biosimilars Filed

The latest drug developments news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Complete Response Letters

Deal Watch: Affimed Teams Up In Immuno-Oncology With Roivant, Artiva

German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.

Deals Business Strategies

Formycon Shifts Strategy On US Lucentis Biosimilar

Formycon has announced a change of strategy for the FYB201 biosimilar ranibizumab candidate being developed with Bioeq. Both firms insist the change is “not expected to have any impact on the timing of the anticipated launch of FYB201 in the US and EU countries.”

Biosimilars Strategy

Amgen And Bioeq Shuttle Stelara Biosimilars Into Phase III Trials

Almost in tandem, Amgen and Bioeq, with partner Formycon, have advanced their biosimilar Stelara (ustekinumab) candidates into Phase III clinical trials. Both sponsors are aiming to wrap their studies up in 2022.

Biosimilars Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • IBC Pharmaceuticals, Inc.
UsernamePublicRestriction

Register